Biolargo Financials

BLGO

FY2025 annual

Revenue $7.8M -56.3% YoY

Net Income -$15.2M -249.4% YoY

EPS (Diluted) Not reported for FY2025

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Biolargo (BLGO) reported $7.8M in revenue for fiscal year 2025, down 56.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BLGO FY2025 2026-05-15

BioLargo’s growth model still depends on external funding because cash burn expanded faster than gross profit in FY2025.

FY2025 kept gross margin near prior levels at 43.9%, but operating cash outflow widened to -$8.3M; that says product-level economics were not the main break, while overhead and development spending were. Cash still ended the year at $3.9M because financing supplied $8.2M, so the steady cash balance hides a direct reliance on new capital.

From FY2022 through FY2024, losses were shrinking as revenue scaled, which suggested some fixed-cost absorption was finally appearing. That changed in the latest year: SG&A reached $11.8M against revenue of $7.8M, so the business lost scale efficiency at the operating level.

Leverage rose as debt-to-equity moved from 0.1x to 0.5x, even though the company still remains more equity-funded than debt-funded. With $3.9M of cash versus -$8.3M of operating cash flow, the financing need came from keeping operations running, not from a capital-intensive asset base.

Financial Health Signals

Financial health score not available

Biolargo does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

Biolargo passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Biolargo reported a net loss of $15.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Biolargo reported an operating loss of $14.9M against $540K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.8M

YoY-56.3%

5Y CAGR+26.1%

10Y CAGR+50.8%

Biolargo generated $7.8M in revenue in fiscal year 2025. This represents a decrease of 56.3% from the prior year.

EBITDA

-$14.6M

YoY-249.5%

Biolargo's EBITDA was -$14.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 249.5% from the prior year.

Net Income

-$15.2M

YoY-249.4%

Biolargo reported -$15.2M in net income in fiscal year 2025. This represents a decrease of 249.4% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$3.9M

YoY+9.4%

5Y CAGR+40.2%

10Y CAGR+8.2%

Biolargo held $3.9M in cash against $2.1M in long-term debt as of fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Shares Outstanding

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

43.9%

YoY-0.3pp

5Y CAGR-6.6pp

10Y CAGR-7.5pp

Biolargo's gross margin was 43.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Return on Equity

-375.8%

YoY-326.7pp

5Y CAGR-124.4pp

Biolargo's ROE was -375.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 326.7 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$2.6M

YoY-10.0%

5Y CAGR+14.1%

10Y CAGR+14.2%

Biolargo invested $2.6M in research and development in fiscal year 2025. This represents a decrease of 10.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BLGO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BLGO annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$4.1M	$7.8M-56.3%	$17.8M+45.4%	$12.2M+107.9%	$5.9M+132.5%	$2.5M+4.1%	$2.4M+30.7%	$1.9M+36.4%	$1.4M+164.3%	$516K+83.6%	$281K+120.3%	$128K+14.4%	$112K-33.6%	$168K+156.2%	$66K-58.0%	$156K
Cost of Revenue	$2.5M	$4.4M-56.1%	$9.9M+63.4%	$6.1M+100.7%	$3.0M+112.0%	$1.4M+18.6%	$1.2M+27.4%	$945K+27.2%	$743K+130.0%	$323K+205.1%	$106K+70.6%	$62K+10.8%	$56K+88.8%	$30K-25.5%	$40K-11.1%	$45K
Gross Profit	$1.6M	$3.4M-56.6%	$7.9M+27.6%	$6.2M+115.4%	$2.9M+159.0%	$1.1M-10.2%	$1.2M+34.1%	$916K+47.5%	$621K+221.8%	$193K+10.1%	$175K+167.5%	$66K+17.9%	$56K-59.8%	$138K+436.8%	$26K-76.9%	$111K
R&D Expenses	$3.3M	$2.6M-10.0%	$2.9M+26.3%	$2.3M+73.0%	$1.3M-3.5%	$1.4M+2.2%	$1.3M-9.1%	$1.5M-14.4%	$1.7M+5.5%	$1.6M+17.9%	$1.4M+101.9%	$685K+6.5%	$643K-13.4%	$742K+93.5%	$384K+285.5%	$99K
SG&A Expenses	$12.6M	$11.8M+26.5%	$9.3M+15.4%	$8.1M+19.7%	$6.7M+9.1%	$6.2M-17.4%	$7.5M+21.7%	$6.1M+15.5%	$5.3M+20.0%	$4.4M+19.2%	$3.7M+4.6%	$3.6M	N/A	N/A	N/A	N/A
Operating Income	-$18.1M	-$14.9M-243.0%	-$4.3M+5.4%	-$4.6M+15.0%	-$5.4M+20.5%	-$6.8M+10.6%	-$7.6M-13.2%	-$6.7M-4.4%	-$6.4M-8.8%	-$5.9M-19.5%	-$4.9M-18.0%	-$4.2M	N/A	N/A	N/A	N/A
Interest Expense	$805K	$540K+660.6%	$71K-22.0%	$91K+71.7%	$53K-77.4%	$234K-87.8%	$1.9M-51.9%	$4.0M+14.4%	$3.5M-9.5%	$3.9M+23.4%	$3.1M+214.6%	$995K+185.7%	$348K+23.6%	$282K-54.3%	$616K-22.3%	$793K
Income Tax	N/A	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$18.8M	-$15.2M-249.4%	-$4.3M+6.5%	-$4.6M+9.4%	-$5.1M+25.6%	-$6.9M+28.9%	-$9.7M+15.2%	-$11.4M-7.0%	-$10.7M	N/A	-$8.1M-59.0%	-$5.1M	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.2M+11.9%	$1.1M+81.0%	$616K-44.2%	$1.1M-60.3%	$2.8M-15.1%	$3.3M-10.5%	$3.7M-16.0%	$4.4M
Cost of Revenue	$573K-12.8%	$657K+33.8%	$491K-32.8%	$731K-46.1%	$1.4M-23.9%	$1.8M-6.6%	$1.9M-27.5%	$2.6M
Gross Profit	$675K+47.4%	$458K+266.4%	$125K-66.4%	$372K-73.8%	$1.4M-4.5%	$1.5M-14.9%	$1.7M+1.5%	$1.7M
R&D Expenses	$1.1M+20.0%	$907K+39.1%	$652K+6.0%	$615K+15.0%	$535K-32.4%	$791K+0.8%	$785K+13.8%	$690K
SG&A Expenses	$3.3M+20.3%	$2.8M-20.6%	$3.5M+12.4%	$3.1M+14.9%	$2.7M+6.6%	$2.5M-2.2%	$2.6M+23.3%	$2.1M
Operating Income	-$3.7M-16.4%	-$3.2M+20.1%	-$4.0M+44.1%	-$7.2M-298.4%	-$1.8M+3.2%	-$1.9M-15.2%	-$1.6M-52.4%	-$1.1M
Interest Expense	$285K+51.6%	$188K0.0%	$188K+30.6%	$144K+25.2%	$115K+23.7%	$93K+111.4%	$44K+238.5%	$13K
Net Income	-$4.0M-17.5%	-$3.4M+17.8%	-$4.1M+42.8%	-$7.2M-284.9%	-$1.9M+2.0%	-$1.9M-10.9%	-$1.7M-63.4%	-$1.1M

Not reported in any period shown, so not listed: EPS (Diluted).

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

BLGO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BLGO annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$8.3M-20.9%	$10.5M+28.1%	$8.2M+68.9%	$4.9M+60.7%	$3.0M-38.8%	$4.9M+36.5%	$3.6M+13.7%	$3.2M+112.9%	$1.5M-29.2%	$2.1M+10.6%	$1.9M+632.8%	$261K+55.9%	$167K-37.8%	$269K+9.1%	$246K
Current Assets	$5.1M-28.3%	$7.1M+12.2%	$6.4M+101.8%	$3.2M+75.1%	$1.8M+19.7%	$1.5M+41.3%	$1.1M+11.5%	$955K-17.5%	$1.2M-42.6%	$2.0M+6.6%	$1.9M+720.1%	$231K+82.7%	$126K-41.8%	$217K+7.2%	$202K
Cash & Equivalents	$3.9M+9.4%	$3.5M+0.3%	$3.5M+91.2%	$1.9M+92.4%	$962K+34.4%	$716K+9.3%	$655K0.0%	$655K-33.8%	$990K-48.2%	$1.9M+8.3%	$1.8M+1041.5%	$154K+67.1%	$92K-38.9%	$151K+17.7%	$128K
Inventory	$310K-6.1%	$330K+115.7%	$153K+27.5%	$120K-50.2%	$241K-13.0%	$277K+1631.3%	$16K-38.5%	$26K-51.9%	$54K+56.8%	$34K-8.0%	$37K+46.7%	$26K-14.5%	$30K-44.7%	$54K-12.7%	$62K
Accounts Receivable	$615K-80.6%	$3.2M+21.3%	$2.6M+145.5%	$1.1M+107.4%	$513K+6.0%	$484K+36.3%	$355K+38.1%	$257K+173.4%	$94K+38.2%	$68K+64.1%	$41K+637.6%	$6K+43.0%	$4K-66.1%	$12K+10.8%	$10K
Total Liabilities	$4.3M+156.9%	$1.7M+22.1%	$1.4M+6905.0%	-$20K+98.8%	-$1.6M-250.4%	$1.1M-81.3%	$5.8M+34.7%	$4.3M-23.1%	$5.6M+62.9%	$3.4M+120.6%	$1.6M+138.7%	$653K-10.8%	$732K+31.1%	$558K-68.3%	$1.8M
Current Liabilities	N/A	N/A	N/A	$1.6M+14.7%	$1.4M	N/A	$4.4M+74.8%	$2.5M-40.9%	$4.2M+265.1%	$1.2M+151.0%	$460K-29.6%	$653K-10.8%	$732K+31.1%	$558K-59.4%	$1.4M
Long-Term Debt	$2.1M+92.7%	$1.1M+273.4%	$289K+21.9%	$237K+31.7%	$180K-64.5%	$507K-27.6%	$700K-45.8%	$1.3M-16.0%	$1.5M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.0M-54.3%	$8.9M+29.3%	$6.8M+40.3%	$4.9M+4.8%	$4.7M+20.6%	$3.9M+279.2%	-$2.2M-43.9%	-$1.5M+63.5%	-$4.1M-209.7%	-$1.3M-476.7%	$352K+189.7%	-$392K+30.6%	-$565K-95.0%	-$290K+80.9%	-$1.5M
Retained Earnings	-$161.3M-7.9%	-$149.5M-1.6%	-$147.1M-2.4%	-$143.6M-3.2%	-$139.1M-5.4%	-$132.0M-6.9%	-$123.5M-10.5%	-$111.7M-10.4%	-$101.2M-10.1%	-$91.9M-9.3%	-$84.1M-6.4%	-$79.0M-4.9%	-$75.3M-3.5%	-$72.8M-7.9%	-$67.5M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$6.7M-22.1%	$8.6M+3.1%	$8.3M-9.0%	$9.1M-27.0%	$12.5M+18.9%	$10.5M0.0%	$10.5M+2.0%	$10.3M
Current Assets	$3.5M-35.7%	$5.4M+6.5%	$5.1M-11.4%	$5.8M-37.1%	$9.2M+27.3%	$7.2M+1.1%	$7.1M-3.5%	$7.4M
Cash & Equivalents	$2.2M-46.9%	$4.1M+6.2%	$3.9M-14.6%	$4.5M+31.0%	$3.5M+35.4%	$2.6M-27.7%	$3.5M-8.6%	$3.9M
Inventory	$303K+3.8%	$292K-5.8%	$310K-24.2%	$409K-7.9%	$444K+20.3%	$369K+11.8%	$330K+38.7%	$238K
Accounts Receivable	$724K-0.8%	$730K+18.7%	$615K-19.2%	$761K-56.1%	$1.7M-58.8%	$4.2M+32.8%	$3.2M-1.3%	$3.2M
Total Liabilities	$9.4M+7.4%	$8.8M+105.0%	$4.3M+67.4%	$2.5M-60.4%	$6.4M+18.8%	$5.4M+226.2%	$1.7M-3.8%	$1.7M
Current Liabilities	$4.8M-3.4%	$4.9M	N/A	N/A	$4.1M+21.0%	$3.4M	N/A	N/A
Long-Term Debt	N/A	N/A	$2.1M	N/A	N/A	N/A	$1.1M+499.4%	$180K
Total Equity	-$1.9M-203.7%	$1.8M-55.8%	$4.0M-38.6%	$6.6M-24.8%	$8.8M+15.1%	$7.6M-14.0%	$8.9M+3.2%	$8.6M
Retained Earnings	-$166.3M-1.7%	-$163.6M-1.4%	-$161.3M-1.9%	-$158.3M-4.3%	-$151.8M-0.8%	-$150.7M-0.8%	-$149.5M-0.7%	-$148.5M

Not reported in any period shown, so not listed: Goodwill.

BLGO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BLGO annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$10.3M	-$8.3M-158.8%	-$3.2M-35.6%	-$2.4M+14.4%	-$2.8M+29.8%	-$3.9M+5.2%	-$4.2M+6.1%	-$4.4M-13.6%	-$3.9M+9.2%	-$4.3M-15.1%	-$3.7M-97.6%	-$1.9M	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$29K	N/A	N/A	N/A	N/A	N/A	$4K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$4.3M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$51K	$435K+133.0%	-$1.3M-175.5%	-$478K-76.4%	-$271K-697.1%	-$34K+72.4%	-$123K-251.4%	-$35K+39.7%	-$58K-100.0%	-$29K+53.2%	-$62K	N/A	N/A	N/A	N/A	-$4K
Financing Cash Flow	$9.0M	$8.2M+85.2%	$4.4M-4.7%	$4.7M+17.8%	$4.0M-6.5%	$4.2M-2.5%	$4.3M-2.8%	$4.5M+22.6%	$3.6M+8.0%	$3.4M-15.1%	$4.0M+12.4%	$3.5M	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.1M-4.8%	-$2.9M-83.5%	-$1.6M+42.4%	-$2.8M-30.3%	-$2.1M-15.7%	-$1.8M+4.5%	-$1.9M-18.3%	-$1.6M
Investing Cash Flow	-$160K-400.0%	-$32K-146.2%	-$13K-105.1%	$256K+33.3%	$192K	$0+100.0%	-$57K-46.2%	-$39K
Financing Cash Flow	$1.3M-59.9%	$3.2M+235.1%	$952K-73.3%	$3.6M+26.0%	$2.8M+227.1%	$866K-45.6%	$1.6M+108.4%	$764K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BLGO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BLGO annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	43.9%-0.3pp	44.2%-6.2pp	50.3%+1.8pp	48.6%+5.0pp	43.6%-6.9pp	50.5%+1.3pp	49.2%+3.7pp	45.5%+8.1pp	37.4%-24.9pp	62.3%+11.0pp	51.3%+1.5pp	49.8%-32.5pp	82.3%+43.0pp	39.3%-32.0pp	71.3%
Operating Margin	-191.3%	-24.4%+13.1pp	-37.5%+54.2pp	-91.6%	-267.8%	-311.8%	-359.8%	-470.1%	-1142.6%	-1755.5%	-3277.5%	N/A	N/A	N/A	N/A
Net Margin	-195.6%	-24.4%+13.6pp	-38.0%+49.2pp	-87.2%	-272.4%	-398.9%	-614.7%	-784.2%	N/A	-2872.4%	-3979.4%	N/A	N/A	N/A	N/A
Return on Equity	-375.8%-326.7pp	-49.1%+18.8pp	-67.9%+37.3pp	-105.2%+43.0pp	-148.2%+103.3pp	-251.4%	N/A	N/A	N/A	N/A	-1443.2%	N/A	N/A	N/A	N/A
Return on Assets	-182.8%-141.4pp	-41.3%+15.3pp	-56.6%+49.0pp	-105.6%+122.4pp	-228.1%-31.8pp	-196.3%+119.6pp	-315.9%+19.9pp	-335.8%	N/A	-382.2%-116.4pp	-265.8%	N/A	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	2.00+0.7x	1.31	N/A	0.24-0.1x	0.38+0.1x	0.27-1.5x	1.75-2.4x	4.11+3.8x	0.35+0.2x	0.17-0.2x	0.39+0.2x	0.15
Debt-to-Equity	0.51+0.4x	0.12+0.1x	0.040.0x	0.050.0x	0.04-0.1x	0.13	N/A	N/A	N/A	N/A	4.43	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-835.8%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	54.1%+13.0pp	41.1%+20.8pp	20.3%-13.4pp	33.7%-17.4pp	51.2%+5.7pp	45.5%-2.3pp	47.8%+8.3pp	39.6%
Operating Margin	-298.7%	-287.4%	-651.1%	-651.0%	-64.9%-7.9pp	-57.0%-12.7pp	-44.3%-19.9pp	-24.4%
Net Margin	-320.5%	-305.4%	-672.4%	-656.8%	-67.8%-9.0pp	-58.8%-11.4pp	-47.4%-23.0pp	-24.4%
Return on Equity	N/A	-190.7%-88.2pp	-102.5%+7.6pp	-110.1%-88.6pp	-21.5%+3.8pp	-25.3%-5.7pp	-19.6%-7.2pp	-12.4%
Return on Assets	-60.0%-20.2pp	-39.8%+10.1pp	-49.8%+29.5pp	-79.3%-64.3pp	-15.1%+3.2pp	-18.3%-1.8pp	-16.5%-6.2pp	-10.3%
Current Ratio	0.73-0.4x	1.10	N/A	N/A	2.25+0.1x	2.14	N/A	N/A
Debt-to-Equity	N/A	4.90+4.4x	0.51+0.1x	0.39-0.3x	0.740.0x	0.71+0.6x	0.12+0.1x	0.02

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Black Swan BSWGF

$36.9M

Nano One Materia NNOMF

$67.3M

Graphene Mfg Gro GMGMF

$189.8M

Kraig Biocraft Laboratories In KBLB

$96.9M

Blue Biofuels Inc BIOF

$32.4M

Where Biolargo Ranks

Frequently Asked Questions

What is Biolargo's annual revenue?

Biolargo (BLGO) reported $7.8M in total revenue for fiscal year 2025. This represents a -56.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biolargo's revenue growing?

Biolargo (BLGO) revenue declined by 56.3% year-over-year, from $17.8M to $7.8M in fiscal year 2025.

Is Biolargo profitable?

No, Biolargo (BLGO) reported a net income of -$15.2M in fiscal year 2025.

What is Biolargo's EBITDA?

Biolargo (BLGO) had EBITDA of -$14.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Biolargo have?

As of fiscal year 2025, Biolargo (BLGO) had $3.9M in cash and equivalents against $2.1M in long-term debt.

What is Biolargo's gross margin?

Biolargo (BLGO) had a gross margin of 43.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biolargo's return on equity (ROE)?

Biolargo (BLGO) has a return on equity of -375.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Biolargo's operating cash flow?

Biolargo (BLGO) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Biolargo's total assets?

Biolargo (BLGO) had $8.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Biolargo spend on research and development?

Biolargo (BLGO) invested $2.6M in research and development during fiscal year 2025.

What is Biolargo's debt-to-equity ratio?

Biolargo (BLGO) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biolargo's return on assets (ROA)?

Biolargo (BLGO) had a return on assets of -182.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Biolargo's cash runway?

Based on fiscal year 2025 data, Biolargo (BLGO) had $3.9M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Biolargo's Piotroski F-Score?

Biolargo (BLGO) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biolargo's earnings high quality?

Biolargo (BLGO) reported a net loss of $15.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biolargo cover its interest payments?

Biolargo (BLGO) reported an operating loss of $14.9M against $540K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.